Positive top-line results shown for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) in adults with binge eating disorder

Shire plc (LSE: SHP, NASDAQ: SHPG) announces positive top-line results from two identically designed randomized placebo-controlled Phase 3 studies evaluating the efficacy and safety of Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) versus placebo in adults with binge eating disorder (BED). In both studies Vyvanse was found to be statistically superior to placebo on the primary efficacy analysis (p-value "We are extremely pleased with these results, and will be working expeditiously to submit an application to the U.S...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Eating Disorders Source Type: news